Search

Your search keyword '"Phase II trial"' showing total 57 results

Search Constraints

Start Over You searched for: Descriptor "Phase II trial" Remove constraint Descriptor: "Phase II trial" Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
57 results on '"Phase II trial"'

Search Results

2. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).

3. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

4. Hypofractionated proton and carbon ion beam radiotherapy for sacrococcygeal chordoma (ISAC): An open label, randomized, stratified, phase II trial.

5. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

6. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.

7. Accelerated partial breast irradiation with 3-dimensional conformal and image-guided intensity-modulated radiotherapy following breast conserving surgery – 7-Year results of a phase II trial.

8. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

9. Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study.

10. Organizing a clinical trial for the new investigator.

11. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).

12. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer.

13. Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.

14. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.

15. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).

16. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.

17. A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer.

18. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501.

19. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial.

20. Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method.

21. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

22. A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

23. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial

24. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

25. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

26. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer

27. Phase II trial of paclitaxel and uracil–tegafur in metastatic breast cancer. TEGATAX trial.

28. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.

29. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

30. Clinical development of dietary supplements: The perils of starting at phase III

31. The Deliverability, Acceptability, and Perceived Effect of the Macmillan Approach to Weight Loss and Eating Difficulties: A Phase II, Cluster-Randomized, Exploratory Trial of a Psychosocial Intervention for Weight- and Eating-Related Distress in People with Advanced Cancer

32. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.

33. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

34. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

35. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

36. Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) Protocol.

37. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

38. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.

39. A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials

40. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia

41. An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

42. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study

43. Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: Multicenter phase II trial

44. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

45. Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

46. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma

47. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer

48. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer

49. Clinical experience with the MammoSite® radiation therapy system for brachytherapy of breast cancer: Results from an international phase II trial

50. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

Catalog

Books, media, physical & digital resources